IMOTIONTECH (01274) received a fixed-point notification.
ZhiXing Technology (01274) announced that the company has recently received some specific notifications, especially announcing two of them...
IMOTIONTECH (01274) announced that the company has recently received a number of designated notifications. It is especially announced that two of these notifications have been received. The first is a designated development notification from a leading self-owned brand in South China (hereinafter referred to as "the new customer"). The company has been selected by this new customer as the supplier of the combined auxiliary driving solution for a mainstream mass-produced vehicle model, and will provide an ADAS domain controller solution based on the Horizon Journey 6B (hereinafter referred to as "J6B") chip. This is also the first batch of designated Horizon J6B row-parking soft and hard integrated domain controller products. The second notification is from a leading new energy vehicle brand in Zhejiang Province, which has designated the development of three overseas vehicle models. The company will provide a combined auxiliary driving solution to help mass-produced vehicle models meet the requirements of the European General Safety Regulations (GSR) and comply with the E-NCAP 2026 five-star safety standard. The first vehicle model is expected to be mass-produced and launched in the first half of next year.
The designation of these two customers signifies that the company's R&D strength has been recognized by new and existing customers, further consolidating and enhancing the company's market competitiveness, enhancing the company's market position in the field of new energy passenger vehicles, and benefiting the future enhancement of the company's market competitiveness and sustainable development capability.
The company will actively promote the above R&D projects. Due to the risks and uncertainties in the research and development process of the combined auxiliary driving solution, the company will actively carry out research and development work on the products, while strengthening risk control to reduce the potential risks caused by market fluctuations.
Related Articles

LIVZON PHARMA (01513): Independent director candidate Wang Zhiyao obtains Shenzhen Stock Exchange Independent Director Training Certification.

The end of the era of the COVID-19 pandemic: Pfizer Inc. (PFE.US) plans to sell off its shares in BioNTech (BNTX.US), marking the conclusion of their iconic vaccine partnership.

BEKE-W(02423) cancelled 37.8061 million repurchased shares on November 13th.
LIVZON PHARMA (01513): Independent director candidate Wang Zhiyao obtains Shenzhen Stock Exchange Independent Director Training Certification.

The end of the era of the COVID-19 pandemic: Pfizer Inc. (PFE.US) plans to sell off its shares in BioNTech (BNTX.US), marking the conclusion of their iconic vaccine partnership.

BEKE-W(02423) cancelled 37.8061 million repurchased shares on November 13th.

RECOMMEND

Younger consumers are dining out less at Chipotle and Cava while still buying Coach handbags
10/11/2025

Target’s deteriorating in-store experience risks recovery — retailer bets on a refined fulfillment model to fix it
10/11/2025

China suspends approval ban on exports of certain metals used in chip and electronics manufacturing to the U.S.
10/11/2025


